More on ACAD
Data
Financials
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $22.40 |
|
|||
| Open | $22.04 | ||||
| 52 Wk High | $42.49 | ||||
| 52 Wk Low | $16.64 | ||||
| Day High | $22.31 | ||||
| Day Low | $21.63 | ||||
| P/E | N/A | ||||
| EPS | $-0.42 | ||||
| Volume | 1,324,043 | ||||
- Form 8-K ACADIA PHARMACEUTICALS For: Mar 03
- Acadia Pharmaceuticals (ACAD) PT Raised to $34 at JPMorgan
- Acadia Pharmaceuticals names Jonathan Poole to board of directors
- Acadia Pharmaceuticals Appoints Jonathan M. Poole to its Board of Directors
- Acadia Pharmaceuticals (ACAD) PT Lowered to $29 at BofA Securities
- Acadia Pharmaceuticals (ACAD) PT Lowered to $29 at BofA Securities
- Acadia Pharmaceuticals plans re-examination after EU rejection of Rett drug
- Acadia Pharmaceuticals Announces Plan to Request Re-Examination Following Negative CHMP Opinion for Trofinetide for the Treatment of Rett Syndrome
- Form SCHEDULE 13D/A ACADIA PHARMACEUTICALS Filed by: BAKER BROS. ADVISORS LP
- Acadia Pharmaceuticals (ACAD) PT Raised to $37 at TD Cowen
Entities mentioned with ACAD
- FDA | View Related Stories »
- Earnings | View Related Stories »
- Twitter | View Related Stories »
- Needham & Company | View Related Stories »
- ARK | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- Definitive Agreement | View Related Stories »
- Show More...
